TERN Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Terns Pharmaceuticals's net margin of -49.65%. Terns Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Terns Pharmaceuticals has a consensus price target of $19.14, signalling upside risk potential of 349.36%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that Terns Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Terns Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Terns Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Terns Pharmaceuticals's net income of -$23.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Terns Pharmaceuticals's net margin of 21.63%. Terns Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.72%.

Terns Pharmaceuticals has a consensus price target of $19.14, signalling upside risk potential of 349.36%. On the other hand Pfizer has an analysts' consensus of $29.06 which suggests that it could grow by 14.79%. Given that Terns Pharmaceuticals has higher upside potential than Pfizer, analysts believe Terns Pharmaceuticals is more attractive than Pfizer.

Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Terns Pharmaceuticals quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Terns Pharmaceuticals's net income of -$23.9M is lower than Pfizer's net income of $3B. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 2.31x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Terns Pharmaceuticals's net margin of --. Terns Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Terns Pharmaceuticals has a consensus price target of $19.14, signalling upside risk potential of 349.36%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1455.56%. Given that Theriva Biologics has higher upside potential than Terns Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Terns Pharmaceuticals.

Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Terns Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Terns Pharmaceuticals's net income of -$23.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Terns Pharmaceuticals's net margin of --. Terns Pharmaceuticals's return on equity of -- beat Viking Therapeutics's return on equity of --.

Terns Pharmaceuticals has a consensus price target of $19.14, signalling upside risk potential of 349.36%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 225.63%. Given that Terns Pharmaceuticals has higher upside potential than Viking Therapeutics, analysts believe Terns Pharmaceuticals is more attractive than Viking Therapeutics.

Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.744%.

Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Terns Pharmaceuticals quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Terns Pharmaceuticals's net income of -$23.9M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.